NASDAQ · ROIV
Roivant Sciences Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ROIV: Nov 09, 2026
Roivant Sciences Ltd. Common Shares is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.52. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Dec 2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Mar 2027 | $-0.55 | $-0.55 | $-0.55 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · MarketBeat · RTTNews- Zacks · Oct 29, 7:35 AM EDTPhathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesPhathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 21, 4:36 PM EDTRoivant Sciences Ltd. Announces Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for BrepocitinibRoivant Sciences Ltd. and its subsidiary, Priovant Therapeutics, Inc., announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis. The program enrolled 371 patients across two identical studies, CLARITY-1 and CLARITY-2, where pat
- MarketBeat · Oct 21, 11:04 AM EDTRoivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis ResultsTrump Index: 6 Companies Linked to Trump’s Cabinet Worth WatchingRoivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflamm
- MarketBeat · Sep 28, 4:02 AM EDTRoivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 MonthsTrump Index: 6 Companies Linked to Trump’s Cabinet Worth WatchingRoivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and exp
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- RTTNews · Sep 23, 9:56 AM EDTRoivant's IMVT-1402 Shows Positive Trends In Lupus Skin Disease Study, But Misses Main Goal(RTTNews) – Roivant (ROIV) announced topline results from a proof-of-concept study evaluating IMVT-1402 (imeroprubart) in patients with cutaneous lupus erythematosus, a chronic autoimmune disease that primarily affects the skin.
- Fintel · Sep 17, 3:13 PM EDTStifel Initiates Coverage of Roivant Sciences with Buy RatingFintel reports that on September 17, 2026, Stifel initiated coverage of Roivant Sciences (NASDAQGS:ROIV) with a Buy recommendation.Roivant Sciences Ltd., based in Switzerland and the United States, is a biopharmaceutical company that develops medicines via a technology-driven pla
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 11, 11:45 AM EDTNew FDA Drug Approvals – August 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.
- RTTNews · Sep 9, 3:06 AM EDTBiotech Stocks At 52-Week Highs – PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH(RTTNews) – The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 recep
- RTTNews · Sep 8, 2:43 PM EDT5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara(RTTNews) – Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech afte
- RTTNews · Sep 8, 9:20 AM EDTRoivant Reports Positive Phase 2 Results For Mosliciguat In PH-ILD; Stock Up 17%(RTTNews) – Roivant (ROIV), a commercial-stage biopharmaceutical company, on Tuesday reported the Phase 2 PHocus trial evaluating Mosliciguat met its primary and secondary endpoints in adults with Pulmonary hypertension associated with interstitial lung disease.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Roivant Sciences Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.